{"title":"高危前列腺癌症患者的最佳治疗","authors":"Katarina Antunac","doi":"10.20471/lo.2018.46.02-03.15","DOIUrl":null,"url":null,"abstract":"Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic lesion and HDR brachytherapy boost should be used as well.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimal treatment of patients with high-risk prostate cancer\",\"authors\":\"Katarina Antunac\",\"doi\":\"10.20471/lo.2018.46.02-03.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic lesion and HDR brachytherapy boost should be used as well.\",\"PeriodicalId\":53700,\"journal\":{\"name\":\"Libri Oncologici\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Libri Oncologici\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20471/lo.2018.46.02-03.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Libri Oncologici","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20471/lo.2018.46.02-03.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Optimal treatment of patients with high-risk prostate cancer
Treatment options in subset of patients with high-risk prostate cancer are various: radical prostatectomy, hormonal therapy, radiation therapy, combined modality approach, addition of chemotherapy. Based on randomised trials data, optimal approach would consist of radical radiotherapy and long term hormonal therapy. If technically possible high dose radiotherapy, hypofractionation, image guided radiotherapy, simultaneous integrated boost on dominant intraprostatic lesion and HDR brachytherapy boost should be used as well.
期刊介绍:
- Genitourinary cancer: the potential role of imaging - Hemoglobin level and neoadjuvant chemoradiation in patients with locally advanced cervical carcinoma